Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | ACACB | O00763 | 5/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16154962 | 0.88 | PNMT (0.51) | HRH3CARM1PNMTDRD2DRD1 | |
| SCHEMBL12680739 | 0.86 | CARM1 (0.46) | ACACBCARM1PRMT6PRMT1MEN1 | |
| SCHEMBL12680741 | 0.85 | CARM1 (0.43) | HRH3ACACBCARM1PRMT6PRMT1 | |
| SCHEMBL13439544 | 0.85 | SIGMAR1 (0.47) | HRH3ACACBDRD2ATM | |
| SCHEMBL18368360 | 0.85 | HTR2C (0.41) | HRH3ACACBPNMTDRD2MEN1 | |
| SCHEMBL13462722 | 0.84 | ACACB (0.42) | HRH3ACACBCARM1PRMT6PRMT1 | |
| SCHEMBL12680766 | 0.84 | ACACB (0.42) | HRH3ACACBCARM1PRMT6PRMT1 | |
| SCHEMBL12680747 | 0.84 | ACACB (0.42) | HRH3ACACBCARM1PRMT6PRMT1 | |
| SCHEMBL12680723 | 0.82 | ACACB (0.54) | ACACBPNMT | |
| SCHEMBL12680763 | 0.81 | SIGMAR1 (0.48) | HRH3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230023009-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SPARCBIO LLC | 2023-01-26 | — | — | US | disclosed |
| US-11358936-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20220009920-A1 | KINASE INHIBITORS | GB005, INC. | 2022-01-13 | — | — | US | disclosed |
| US-20210171465-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358936-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | HRH3 3039/4885ACACB 522/4885CARM1 3573/4885 |
| US-20210171465-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | HRH3 3039/4885ACACB 522/4885CARM1 3573/4885 |
| US-20220009920-A1 | KINASE INHIBITORS | BTK, LYN, LCK | HRH3 3555/4885ACACB 1285/4885CARM1 2301/4885 |
| US-20230023009-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | HRH3 621/4885ACACB 2518/4885CARM1 1525/4885 |
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | HRH3 2838/4885ACACB 2132/4885CARM1 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.